Clinical Approaches and Outcomes of Serous Endometrial Cancer in a Large Tertiary Referral Centre Background Currently there is a lack of consensus on the uniform management of Serous Endometrial cancer, owing to the fact that often these patients are poor surgical and oncology candidates. Aims To describe the clinical approach and outcomes of 57 patients with Serous Endometrial cancer in a larger tertiary referral centre. Methods A retrospective study from January 2009 to January 2018 of all cases of predominantly serous histology. Data parameters including treatment regimens and survival patterns were recorded. Results A total of 57 patients with an average age at presentation of 67.5 years (47-92) were included in the study. Upon diagnosis, 9/57 (16%) had an ASA 3 and were deemed un-suitable for surgical intervention. 5/9 (55.5%) received neoadjuvant chemotherapy, 2/9 (22.2%) received palliative RT while 2/9 (22.2%) declined treatment. 48/57 (84.2%) had upfront de-bulking surgery with a wide variation in the choice of adjuvant therapy; Chemo+RT 18/48 (37.5%), Chemo Only 16/48 (33.3%), RT only 3/48 (6.2%), Progesterone only 2/48 (4.1%), No Therapy 9/48 (5.9%). The 18 month progression free survival was 51.1%. There was a statistically significant difference in the 18 month progression free survival between the Chemo+RT and the Chemo only group; (71% V 42%: P<0.05). Conclusion A larger percentage of these patients receive neoadjuvant treatment only compared to their Endometrioid counterparts. There is a wide variation in adjuvant treatments with those receiving combined chemotherapy and radiotherapy having higher progression free survivals at 18 months.
No datasets are available for this submission.
No license information is available for this submission.